CytoMed Therapeutics

Recent Finacing

Equity

Recent Raise

$0.5M

CytoMed Therapeutics is a Singapore-based biotechnology company developing donor-derived allogeneic γδ T-cell immunotherapies while incubating new ventures such as LongevityBank for personalized autologous cell treatments.

Central Region, Singapore

11-50

Publicly Traded

cytomed.sg

Highlights

Focus Areas

Biotechnology

Recent Investors

Financials

$24.4M

Valuation as of 11/06/2025

$0.5M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at CytoMed Therapeutics.